A Prospective Randomised, Open-Labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.

Trial Profile

A Prospective Randomised, Open-Labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Sirolimus (Primary) ; Immunosuppressants
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms SiLVER
  • Most Recent Events

    • 27 Sep 2017 Results presented at the 18th Congress of the European Society for Organ Transplantation
    • 11 Aug 2010 Trial design was reported in the journal BMC Cancer.
    • 03 Jun 2009 Patient enrolment is expected to be complete in early 2009 according an abstract presented at the 2009 ATS meeting. The first interim analysis of the primary endpoint is expected in mid-2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top